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INTRODUCTION
The alternatives to total abdominal hysterectomy include
denial of service, vaginal hysterectomy, laparoscopic-assisted
vaginal hysterectomy, laparoscopic supracervical hysterecto-
my, endometrial ablation, and myomectomy/myolysis.
There are 650,000 hysterectomies performed each year in
the United States with 75% of these being abdominal hys-
terectomies and only 25% being vaginal hysterectomies.
The goal of healthcare reform should be to eliminate unnec-
essary hysterectomies and to convert abdominal hysterec-
tomies to less invasive procedures.
Sixteen percent of all hysterectomies have been found to be
inappropriate therapy with 25% of hysterectomies in
younger women and 8% of hysterectomies in older women
deemed unnecessary.
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Once the issue of the appropriateness of surgery has been
dealt with, the issue becomes "Is the choice of abdominal
hysterectomy appropriate? or is another therapy possible?"
DEFINITIONS
By way of definitions, an abdominal hysterectomy is
removal of the uterus with or without the ovaries through
an incision approximately 5 inches wide in the abdomen. A
vaginal hysterectomy is the removal of the uterus with or
without the ovaries through an incision in the vaginal area.
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Endometrial ablation refers to hysteroscopic removal or
destruction of the lining of the uterus down to the level of
the uterine muscle.
Laparoscopic-assisted vaginal hysterectomy refers to the
use of a laparoscope to allow the performance of hysterec-
tomy through a vaginal means that would have otherwise
required an abdominal approach. Laparoscopic supracer-
vical hysterectomy refers to removal of the uterus utilizing
a laparoscope but leaving the cervix in place. Laparoscopic
myomectomy refers to removal of fibroid tumors from the
uterus and subsequent removal of the fibroids from the
pelvic cavity by morcellation or extraction using minimally
invasive techniques. Myolysis refers to laparoscopic
destruction of fibroid tumors using either laser or electrical
energy so that they do not recur.
INDICATIONS
The indications for the various therapies are shown in
Table 1. An abdominal hysterectomy is appropriate for
fibroids, bleeding, pain and cancer. Laparoscopic suprac-
ervical hysterectomy is appropriate for fibroids, bleeding,
and pain but is not appropriate for a cancer patient. Using
this table, one can seek out an alternative to abdominal
hysterectomy for the specific problem with which the
patient presents.
CRITICAL PARAMETERS
The critical parameters for the surgical procedures that are
alternatives to the abdominal hysterectomy are shown in
Table 2.
An abdominal hysterectomy requires 4 to 5 days of hospi-
tal stay with a recovery time for patients of 6 to 8 weeks.
Vaginal hysterectomy requires a hospital stay of only 1 to 2
days and 7 to 14 days of recovery time. Both the laparo-
scopic-assisted vaginal hysterectomy and laparoscopic
supracervical hysterectomy have comparable lengths of
stay and recovery times to vaginal hysterectomy.
Endometrial ablation requires only 30 minutes to 1 hour to
complete and a brief stay in an outpatient setting. It
requires a recovery time of only 2 to 4 days. Myolysis has
similar parameters to the endometrial ablation.
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Conversion of abdominal hysterectomy to alternative pro-
cedures potentially could save 4 to 6 weeks of recovery
time and 2 to 4 hospital days per patient. If these alterna-
tive procedures could be performed for all 487,500 patients
currently being treated with abdominal hysterectomy, this
would amount to almost 2 million hospital days saved per
year.
A goal of healthcare reform should be to convert as many
abdominal procedures as possible to the alternatives to
obtain as much of the savings as possible both in patient
recovery and in hospital days.
Dysfunctional Uterine Bleeding:
Dysfunctional uterine bleeding is a major cause for hys-
terectomy. Endometrial ablation can frequently replace
hysterectomy for the treatment of bleeding disorders. This
procedure takes 30 minutes to 1 hour to perform, requires
only a few hours of observation in an outpatient setting
postoperatively, and has a very short recovery time for the
patient.
In order to ensure that patients are satisfied with the results
of the procedure, however, it is important that the ablation
be performed thoroughly.
It has been demonstrated that the success of endometrial
ablation is dependent upon uniform destruction of the
endometrium and superficial portion of the myometrium.
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In order to ensure this uniform destruction of the
endometrium, GnRH agonists are used for pretreatment for
a period of one to three months. GnRH agonists prepare
the endometrium by uniformly reducing thickness, decreas-
ing edema, and avoiding pseudodecidual reaction usually
present with other hormonal treatment.
Uterine Fibroids:
Uterine fibroids can be treated by myomectomy, myolysis,
laparoscopic-assisted vaginal hysterectomy, laparoscopic
supracervical hysterectomy, or vaginal hysterectomy. It has
been shown that uterine fibroids contain estrogen receptors
and are responsive to hormonal manipulation. Since GnRH
agonists induce a state of hypoestrogenism, they are effec-
tive in treating uterine fibroids. In fact, uterine fibroid vol-
ume will decrease by an average of 57% over a six-month
course of treatment by GnRH agonists.
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If uterine fibroids are causing menorrhagia with anemia,
uterine pressure or pain, or are otherwise causing symp-
toms, then treatment is appropriate. Twenty-seven percent
or 175,000 of the hysterectomies performed in the United
States annually are performed for fibroids. In addition,
myomectomy is performed in 28,000 patients per year.
Because GnRH agonists shrink the uterus and fibroids, it is
possible to administer a GnRH agonist for two months and
increase the frequency of vaginal hysterectomy over
abdominal hysterectomy. In fact, in one study, 76% of
GnRH agonist-treated patients had a vaginal hysterectomy
versus 16% of nontreated patients.
4 The use of GnRH ago-
nists can make possible a conversion from abdominal hys-
terectomy to either vaginal hysterectomy or laparoscopic-
assisted vaginal hysterectomy or laparoscopic supracervical
hysterectomy.
Laparoscopic myolysis can also be proposed as an alterna-
tive to abdominal hysterectomy in cases of large or multi-
ple intramural fibroids in women over 40 who do not
desire to bear children but who wish to avoid hysterecto-
my.
5,
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Laparoscopic myolysis is performed by inserting a laser
fiber or bipolar electrosurgery electrode into the fibroid.
This is performed after pretreatment by GnRH agonist for a
period of two to three months. After myolysis has been
performed, a full six-month course of GnRH agonist treat-
ment is completed. As a result of this therapy, uterine vol-
ume can be reduced by 41% within one year.
5 In 200 cases
using a combination of laser and GnRH agonists, a reduc-
tion in volume of 70% of the fibroid size was accomplished
at one year.
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Myolysis, therefore, can be considered an effective therapy
for the reduction of fibroid size and can be proposed as an
alternative to myomectomy or hysterectomy in selected
patients.
Laparoscopic myomectomy can also be accomplished. In
one study, 92 myomas were removed in 43 patients. To
avoid the need for transfusion, the patients were systemat-
ically treated preoperatively with GnRH agonist.
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Endometriosis:
For treatment of pain, both laparoscopic surgery with pro-
cedures such as laparoscopic excision of endometriosis,
laparoscopic uterosacral nerve vaporization, and laparo-
scopic presacral neurectomy can be performed to prevent
the need for hysterectomy. In one study, GnRH agonists
were given for six months for the treatment of endometrio-
sis without surgical intervention. These patients were fol-
lowed for a period of five years, and it was found that
46.6% were cured by the six-month course of GnRH ago-
nist therapy.
8
In patients with pelvic pain and endometriosis, a trial of
medical therapy with GnRH agonists is warranted because
long-lasting benefits occur in about half of the women treat-
ed. Half of these patients, however, will have recurrence of
the disease, requiring retreatment or surgical intervention.
8
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Alternatives to abdominal hysterectomy.
Indications for uterine treatment.
*with laparoscopic node dissection.
CONCLUSION
In conclusion, pretreatment with GnRH agonist has been
demonstrated to be an effective means to allow many who
previously would have required abdominal surgery to con-
vert to less traumatic alternatives. These alternatives would
permit a great savings for the patient in hospital time, pain,
suffering, and time off work as well as decreasing the risks
of surgery in terms of infection, blood loss, and complica-
tions.
Pretreatment with GnRH agonists can have the following
effects:
1) Conversion of abdominal to vaginal surgery.
2) Conversion of abdominal to laparoscopic-assisted vagi-
nal surgery.
3) Conversion of abdominal hysterectomy to endometrial
ablation.
4) Elimination of the need for surgery altogether.
5) Conversion of need for hysterectomy to myomectomy
or myolysis.
6) Conversion of abdominal surgery to laparoscopic pro-
cedures.
The integration of GnRH agonists into our treatment arma-
mentarium holds forth an opportunity for great benefits to
our patients in our quest to perform more minimally inva-
sive and less traumatic surgical procedures.
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Table 2.
Alternatives to total abdominal hysterectomy.
Critical parameters for surgical procedures.
PROCEDURE
Abdominal hysterectomy
Vaginal
hysterectomy
LAVH
LSH
Endometrial
Ablation
Myomectomy/
Myolysis
Length of Stay
4-5 days
1-2 days
1-2 days
1 day
Less than 1 day
Less than 1 day
Surgery Time
1-2 hours
1-2 hours
1.5 to 3 hours
1-2 hours
30 minutes to 1
hour
1-2 hours
Recovery Time
6-8 weeks
7-14 days
14 days
7-14 days
2-4 days
2-4 hours
Complication Rate
10-15%
3-7%
3-7%
1-4%
1-2%
Less than 3%
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